Literature DB >> 30855205

Association of Overt and Subclinical Hyperthyroidism During Weeks 4-8 with Adverse Pregnancy Outcomes.

Yindi Zhang1, Yushu Li1, Zhongyan Shan1, Yingxi Xu2, Chenyan Li1, Xiaochen Xie1, Yan Li1, Weiwei Wang1, Jinyuan Mao1, Weiping Teng1.   

Abstract

Background: Although increasing data suggest that hyperthyroidism is associated with adverse pregnancy outcomes, there are only a few reports with different conclusions on whether the mild transient reduction in thyrotropin (TSH) with or without free thyroxine (FT4) elevation during the early stage of pregnancy also causes adverse pregnancy outcomes. Subjects and
Methods: We analyzed data from 3,783 women in this study from August 2011 to December 2013. Participants completed a questionnaire survey. Samples of blood were obtained in the 4th-8th week of pregnancy and their TSH, FT4, thyroid peroxidase antibody, and thyroglobulin antibody were measured. We divided the participants into overt hyperthyroidism group (OHG), subclinical hyperthyroidism group (SHG), and control group based on their blood results and followed up on their pregnancy outcomes.
Results: (1) The serum level of FT4 in the SHG was much higher than the control group (p < 0.05). No difference was found in the TSH between the OHG and SHG. The positive rate of autoimmune thyroid antibodies in the OHG (25.6%) was significantly higher than that in the SHG (14.2%) and control group (13.9%) (p < 0.05), whereas there was no difference between the SHG and control group. (2) The SHG had a lower incidence of miscarriage (1.7% vs. 7.2%; OR = 0.218, p = 0.016) than the control group, and the OHG had a higher incidence of placenta previa (3.3% vs. 0.8%; OR = 4.366, p = 0.039) than the control group. (3). We used a binary logistic regression to take other factors into consideration and found that subclinical hyperthyroidism was associated with a lower risk of abortion (OR = 0.206; 95% CI = 0.050-0.840; p = 0.028) but higher risk of preeclampsia (OR = 5.143; 95% CI = 1.463-18.076; p = 0.011) and placental abruption (OR = 4.676; 95% CI = 1.017-21.509; p = 0.048), and overt hyperthyroidism may increase the incidence of placenta previa (OR = 4.193; 95% CI = 1.222-14.382; p = 0.023). Conclusions: Subclinical hyperthyroidism during weeks 4-8 of pregnancy may be associated with the decreased incidence of abortion but might be a risk factor for preeclampsia and placental abruption. Meanwhile, pregnancy with overt hyperthyroidism may be an independent risk factor for placenta previa.

Entities:  

Keywords:  adverse pregnancy outcomes; hyperthyroidism; pregnancy; reduced TSH; subclinical hyperthyroidism

Mesh:

Substances:

Year:  2019        PMID: 30855205     DOI: 10.1089/jwh.2018.7180

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  5 in total

1.  Combined detection of ACL and β2-GP1 in diagnosis of adverse pregnancy.

Authors:  Wei Zhang; Dong Wang; Weixin Yuan; Shuiping Yao
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

2.  Effect of Hyperthyroidism Control During Pregnancy on Maternal and Fetal Outcome: A Systematic Review and Meta-Analysis.

Authors:  Jose Mario Alves Junior; Wanderley Marques Bernardo; Laura Sterian Ward; Danilo Villagelin
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-24       Impact factor: 6.055

3.  Pregnancy Outcomes in Women with Thyroid Diseases.

Authors:  Tomomi Kotani; Kenji Imai; Takafumi Ushida; Yoshinori Moriyama; Tomoko Nakano-Kobayashi; Satoko Osuka; Hiroyuki Tsuda; Seiji Sumigama; Eiko Yamamoto; Fumie Kinoshita; Akihiro Hirakawa; Akira Iwase; Fumitaka Kikkawa; Hiroaki Kajiyama
Journal:  JMA J       Date:  2022-02-28

4.  Epidemiology, Risk Factors, and Perinatal Outcomes of Placental Abruption-Detailed Annual Data and Clinical Perspectives from Polish Tertiary Center.

Authors:  Monika Bączkowska; Katarzyna Kosińska-Kaczyńska; Magdalena Zgliczyńska; Robert Brawura-Biskupski-Samaha; Beata Rebizant; Michał Ciebiera
Journal:  Int J Environ Res Public Health       Date:  2022-04-23       Impact factor: 4.614

5.  Evaluation of anti-Müllerian hormone in pre-menopausal women stratified according to thyroid function, autoimmunity and age.

Authors:  Massimo Giusti; Miranda Mittica
Journal:  Thyroid Res       Date:  2022-08-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.